CDK4 and glioblastoma: In conclusion, these studies suggest that GLR2007 may be as efficacious in the treatment of GBM and other advanced solid tumor cancers as the approved CDK4/6 inhibitors, supporting further investigation of GLR2007 through clinical trials.